Girolama Alessandra Marfia
Overview
Explore the profile of Girolama Alessandra Marfia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M, et al.
J Neurol
. 2025 Feb;
272(2):179.
PMID: 39891770
The classification of multiple sclerosis (MS) into the two distinct phases of relapsing-remitting and progressive, including primary progressive and secondary progressive phenotypes (PPMS and SPMS, respectively) has long been accepted;...
2.
Dolcetti E, Annovazzi P, Clerico M, Cocco E, Conte A, Marfia G, et al.
Curr Neuropharmacol
. 2024 Sep;
PMID: 39313879
In multiple sclerosis (MS), alongside the physical symptoms, individuals often grapple with anxiety and depressive symptoms as prevalent comorbidity. Mood disturbances, frequently undertreated in clinical practice, significantly impact the quality...
3.
Bruno A, Annovazzi P, Clerico M, Cocco E, Conte A, Marfia G, et al.
Curr Neuropharmacol
. 2024 Sep;
PMID: 39279696
With the recent introduction of a number of highly effective disease-modifying treatments (DMTs) and the resulting almost complete prevention of acute relapses in many patients with multiple sclerosis (MS), the...
4.
Landi D, Bartolomeo S, Bovis F, Amato M, Bonavita S, Borriello G, et al.
Mult Scler
. 2024 Sep;
30(11-12):1503-1513.
PMID: 39263885
Background: Evidence on the impact of dimethyl fumarate (DMF) during pregnancy in women with multiple sclerosis (MS) is limited. Objectives: To investigate disease activity and pregnancy outcomes in a retrospective...
5.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2008-2015.
PMID: 38970214
Objective: No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare...
6.
Signoriello E, Signori A, Lus G, Romano G, Marfia G, Landi D, et al.
Mult Scler Relat Disord
. 2024 May;
87:105594.
PMID: 38718748
Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in...
7.
Doneddu P, Gentile L, Cocito D, Fazio R, Luigetti M, Briani C, et al.
Eur J Neurol
. 2024 Feb;
31(5):e16248.
PMID: 38376074
Background And Purpose: This study aimed to assess the diagnostic criteria, ancillary investigations and treatment response using real-life data in multifocal motor neuropathy (MMN) patients. Methods: Clinical and laboratory data...
8.
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, et al.
J Neurol
. 2024 Feb;
271(5):2182-2194.
PMID: 38366072
Objective: Multiple sclerosis (MS) is a complex disorder in which environmental and genetic factors interact modifying disease risk and course. This multicentre, case-control study involving 18 Italian MS Centres investigated...
9.
Lorefice L, Ferraro O, Fenu G, Amato M, Bresciamorra V, Conte A, et al.
J Neurol
. 2024 Jan;
271(4):1630-1637.
PMID: 38172380
Background: Generally infrequent, multiple sclerosis (MS) with late onset (LOMS) is characterized by an onset over the age of 50 and a mainly progressive course, while relapsing-remitting (RR) forms are...
10.
de Lorenzo A, Liberatore G, Doneddu P, Manganelli F, Cocito D, Briani C, et al.
Eur J Neurol
. 2024 Jan;
31(4):e16190.
PMID: 38165011
Background And Purpose: There are different criteria for the diagnosis of different variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guidelines provide...